These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 39012908)

  • 1. Beyond the PSA: The hidden costs of screening in prostate cancer.
    Sanyal C; Ragavan MV
    Cancer; 2024 Oct; 130(19):3272-3274. PubMed ID: 39012908
    [No Abstract]   [Full Text] [Related]  

  • 2. Cost-effectiveness analysis of PSA-based mass screening: Evidence from a randomised controlled trial combined with register data.
    Booth N; Rissanen P; Tammela TLJ; Kujala P; Stenman UH; Taari K; Talala K; Auvinen A
    PLoS One; 2019; 14(11):e0224479. PubMed ID: 31689326
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostate-Specific Antigen (PSA)-Based Population Screening for Prostate Cancer: An Economic Analysis.
    Tawfik A
    Ont Health Technol Assess Ser; 2015; 15(11):1-37. PubMed ID: 26366237
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Response.
    Heijnsdijk EA; de Koning HJ
    J Natl Cancer Inst; 2015 Jun; 107(6):djv111. PubMed ID: 25888717
    [No Abstract]   [Full Text] [Related]  

  • 5. Screening for prostate cancer: time to put all the data on the table.
    Haines IE; Ablin RJ; Miklos GL
    BMJ; 2016 May; 353():i2574. PubMed ID: 27226459
    [No Abstract]   [Full Text] [Related]  

  • 6. Re: Cost-Effectiveness of Prostate Cancer Screening: A Simulation Study Based on ERSPC Data.
    Taneja SS
    J Urol; 2015 Jul; 194(1):113-4. PubMed ID: 26088223
    [No Abstract]   [Full Text] [Related]  

  • 7. Re: Cost-effectiveness of prostate cancer screening: a simulation study based on ERSPC data.
    Noordzij MA; Blanker MH
    J Natl Cancer Inst; 2015 Jun; 107(6):djv110. PubMed ID: 25888716
    [No Abstract]   [Full Text] [Related]  

  • 8. Cost-effectiveness of prostate cancer screening: a simulation study based on ERSPC data.
    Heijnsdijk EA; de Carvalho TM; Auvinen A; Zappa M; Nelen V; Kwiatkowski M; Villers A; Páez A; Moss SM; Tammela TL; Recker F; Denis L; Carlsson SV; Wever EM; Bangma CH; Schröder FH; Roobol MJ; Hugosson J; de Koning HJ
    J Natl Cancer Inst; 2015 Jan; 107(1):366. PubMed ID: 25505238
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The cost-effectiveness of prostate health index for prostate cancer detection in Chinese men.
    Teoh JY; Leung CH; Wang MH; Chiu PK; Yee CH; Ng CF; Wong MC
    Prostate Cancer Prostatic Dis; 2020 Dec; 23(4):615-621. PubMed ID: 32606435
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The costs of identifying undiagnosed prostate cancer in asymptomatic men in New Zealand general practice.
    Lao C; Brown C; Obertová Z; Edlin R; Rouse P; Hodgson F; Holmes M; Gilling P; Lawrenson R
    Fam Pract; 2013 Dec; 30(6):641-7. PubMed ID: 24055993
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Cost-Effectiveness of Prostate Cancer Detection with the Use of Prostate Health Index.
    Heijnsdijk EA; Denham D; de Koning HJ
    Value Health; 2016; 19(2):153-7. PubMed ID: 27021748
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate cancer: Numeracy and understanding of risk reduction of PSA screening.
    Subramanian V; Kattan MW
    Nat Rev Urol; 2018 Apr; 15(4):208-209. PubMed ID: 29460924
    [No Abstract]   [Full Text] [Related]  

  • 13. Budget impact analysis of a new prostate cancer risk index for prostate cancer detection.
    Nichol MB; Wu J; An JJ; Huang J; Denham D; Frencher S; Jacobsen SJ
    Prostate Cancer Prostatic Dis; 2011 Sep; 14(3):253-61. PubMed ID: 21537346
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost implications of PSA screening differ by age.
    Rao K; Liang S; Cardamone M; Joshu CE; Marmen K; Bhavsar N; Nelson WG; Ballentine Carter H; Albert MC; Platz EA; Pollack CE
    BMC Urol; 2018 May; 18(1):38. PubMed ID: 29743049
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate-specific antigen, prostate cancer screening, and the pathologist: what should be our role?
    Jackson BR
    Arch Pathol Lab Med; 2013 Mar; 137(3):308-9. PubMed ID: 22799565
    [No Abstract]   [Full Text] [Related]  

  • 16. Overdetection, overtreatment and costs in prostate-specific antigen screening for prostate cancer.
    Heijnsdijk EA; der Kinderen A; Wever EM; Draisma G; Roobol MJ; de Koning HJ
    Br J Cancer; 2009 Dec; 101(11):1833-8. PubMed ID: 19904272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Does a low PSA at 60 years old exclude the risk of developing prostate carcinoma?].
    Zürcher S
    Rev Med Suisse; 2014 Jun; 10(434):1316. PubMed ID: 25073308
    [No Abstract]   [Full Text] [Related]  

  • 18. [Prostate cancer screening: Reasons of controversy].
    Delporte G; Villers A; Penel N
    Bull Cancer; 2018 Dec; 105(12):1111-1118. PubMed ID: 30458966
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PSA screening, prostate biopsy, and treatment of prostate cancer in the years surrounding the USPSTF recommendation against prostate cancer screening.
    Kearns JT; Holt SK; Wright JL; Lin DW; Lange PH; Gore JL
    Cancer; 2018 Jul; 124(13):2733-2739. PubMed ID: 29781117
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate cancer: a review of common underwriting problems, Part 1.
    Richie RC; Swanson JO
    J Insur Med; 2004; 36(3):242-54. PubMed ID: 15495440
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.